ATE469979T1 - Isolierung von biologischen modulatoren aus bibliotheken mit biologisch vielvältigen genfragmenten - Google Patents

Isolierung von biologischen modulatoren aus bibliotheken mit biologisch vielvältigen genfragmenten

Info

Publication number
ATE469979T1
ATE469979T1 AT06003767T AT06003767T ATE469979T1 AT E469979 T1 ATE469979 T1 AT E469979T1 AT 06003767 T AT06003767 T AT 06003767T AT 06003767 T AT06003767 T AT 06003767T AT E469979 T1 ATE469979 T1 AT E469979T1
Authority
AT
Austria
Prior art keywords
libraries
isolation
activity
gene fragments
diverse gene
Prior art date
Application number
AT06003767T
Other languages
English (en)
Inventor
Paul Michael Watt
Wayne Robert Thomas
Original Assignee
Phylogica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phylogica Ltd filed Critical Phylogica Ltd
Application granted granted Critical
Publication of ATE469979T1 publication Critical patent/ATE469979T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06003767T 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibliotheken mit biologisch vielvältigen genfragmenten ATE469979T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13271199P 1999-05-05 1999-05-05

Publications (1)

Publication Number Publication Date
ATE469979T1 true ATE469979T1 (de) 2010-06-15

Family

ID=22455261

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00922330T ATE320486T1 (de) 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten
AT06003767T ATE469979T1 (de) 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibliotheken mit biologisch vielvältigen genfragmenten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00922330T ATE320486T1 (de) 1999-05-05 2000-05-05 Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten

Country Status (10)

Country Link
US (7) US6994982B1 (de)
EP (4) EP1179059B1 (de)
AT (2) ATE320486T1 (de)
AU (6) AU771534B2 (de)
CA (2) CA2721199A1 (de)
DE (2) DE60044514D1 (de)
DK (1) DK2230303T3 (de)
ES (2) ES2260009T3 (de)
NZ (1) NZ515329A (de)
WO (1) WO2000068373A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
FR2824844B1 (fr) * 2001-05-18 2003-09-19 Genoway Procede de clonage par double selection et vecteurs pour ce procede
GB0126887D0 (en) * 2001-11-08 2002-01-02 Univ London Method for producing and identifying soluble protein domains
AU2002365538A1 (en) * 2001-11-27 2003-06-10 Nexyte Ab Production of eukaryotic proteins and nucleic acid molecules in c. elegans
US20050153304A1 (en) * 2003-04-10 2005-07-14 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Multivariate profiling of complex biological regulatory pathways
CA2568644C (en) * 2004-06-03 2015-11-24 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
CA2950465A1 (en) 2006-02-20 2007-08-30 Phylogica Limited Method of constructing and screening libraries of peptide structures
WO2008034161A1 (en) 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor
FR2910493B1 (fr) 2006-12-20 2012-12-14 Bio Modeling Systems Ou Bmsystems Procede de diversification aleatoire d'une sequence genetique permettant de preserver l'identite de certains segments internes de ladite sequence genetique
WO2008154700A1 (en) 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
WO2013116903A1 (en) 2012-02-10 2013-08-15 Phylogica Limited Methods for the characterisation of interaction sites on target proteins
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
WO2016105542A2 (en) 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
US10363299B2 (en) 2015-02-19 2019-07-30 University Of Virginia Patent Foundation Compositions and methods for preventing and treating rhinovirus infections
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
SG11201804003VA (en) 2015-11-19 2018-06-28 Asclepix Therapeutics Llc Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
EP3998281A1 (de) 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8-bindemittel
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
EP3454887B1 (de) 2016-05-13 2021-01-20 Orionis Biosciences BV Zielgerichtete mutanten-interferon-beta und verwendungen davon
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
AU2017339970A1 (en) 2016-10-04 2019-04-18 Asclepix Therapeutics, Llc Compounds and methods for activating Tie2 signaling
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
CN110546160A (zh) 2017-02-06 2019-12-06 奥里尼斯生物科学公司 靶向嵌合蛋白及其用途
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3661536A4 (de) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
EP3924389A4 (de) 2019-02-15 2023-06-14 Integral Molecular, Inc. Claudin-6-antikörper und deren verwendungen
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0440147B2 (de) 1990-02-01 2014-05-14 Siemens Healthcare Diagnostics Products GmbH Herstellung und Verwendung von Genbanken menschlicher Antikörper ("Human-Antikörper-Bibliotheken")
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US5470953A (en) * 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5883074A (en) 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
EP0830457A1 (de) 1995-06-07 1998-03-25 Microcide Pharmaceuticals, Inc. Verfahren zur auffindung von antimikrobiellen zielen
US20030215798A1 (en) * 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US5763239A (en) 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US5843698A (en) * 1997-04-30 1998-12-01 Universal Ventures Deleteriously affecting members of a target species by exposure to a component of symbiont or food source of an adjoiner species that is symbiotic with the target species
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6583275B1 (en) * 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
WO1999035282A1 (en) 1998-01-09 1999-07-15 Tvw Telethon Institute For Child Health Research Peptide detection method
JP2002502038A (ja) * 1998-01-29 2002-01-22 ミラー，サミュエル プロテオーム分析のための高密度アレイ及びその方法及び組成物
US6316223B1 (en) 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6287825B1 (en) * 1998-09-18 2001-09-11 Molecular Staging Inc. Methods for reducing the complexity of DNA sequences
US6720139B1 (en) * 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6074815A (en) * 1999-03-08 2000-06-13 Universal Ventures Selection of test species for testing to identify components thereof that deleteriously affect a target species member
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6150127A (en) * 1999-11-30 2000-11-21 Universal Ventures Causing a desirable change in a behavior pattern
WO2001079480A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN1447862A (zh) 2000-07-12 2003-10-08 加州理工学院 一种由蛋白质的一级结构序列确定蛋白质三维结构的方法

Also Published As

Publication number Publication date
AU2009251209A1 (en) 2010-01-28
ES2402878T3 (es) 2013-05-10
US20100227777A1 (en) 2010-09-09
EP1696038A3 (de) 2007-02-14
US20050287580A1 (en) 2005-12-29
EP1179059B1 (de) 2006-03-15
EP1179059A1 (de) 2002-02-13
AU2003302489A1 (en) 2004-09-09
DE60044514D1 (de) 2010-07-15
EP1696038A2 (de) 2006-08-30
AU2006200082A1 (en) 2006-02-09
EP2230303A1 (de) 2010-09-22
AU4275900A (en) 2000-11-21
US20080139401A1 (en) 2008-06-12
EP1696038B1 (de) 2010-06-02
NZ515329A (en) 2004-05-28
US20110092386A1 (en) 2011-04-21
DE60026695D1 (de) 2006-05-11
DK2230303T3 (da) 2013-04-15
AU2009251209B2 (en) 2012-10-11
CA2372464A1 (en) 2000-11-16
AU771534B2 (en) 2004-03-25
CA2721199A1 (en) 2000-11-16
ATE320486T1 (de) 2006-04-15
EP1696037A3 (de) 2007-01-24
DE60026695T2 (de) 2006-11-02
EP2230303B1 (de) 2013-01-16
ES2260009T3 (es) 2006-11-01
EP1179059A4 (de) 2003-01-22
AU2003302489B8 (en) 2008-05-08
US6994982B1 (en) 2006-02-07
CA2372464C (en) 2012-07-31
WO2000068373A1 (en) 2000-11-16
US20120214709A1 (en) 2012-08-23
AU2003302489B2 (en) 2008-03-06
AU2011200020A1 (en) 2011-01-27
US20150344875A1 (en) 2015-12-03
AU2008200790A1 (en) 2008-03-13
EP1696037A2 (de) 2006-08-30
AU2006200082B2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
DE60044514D1 (de) Isolierung von biologischen Modulatoren aus Bibliotheken mit biologisch vielvältigen Genfragmenten
NO883592L (no) Enzym.
ATE313625T1 (de) ßFUNCTIONAL GENOMICSß UNTER VERWENDUNG VON ZINK FINGER PROTEINEN
DE60303591D1 (de) System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
ATE551352T1 (de) Peptidakzeptorbindungsverfahren
DE69932813D1 (de) Nukleinsäurebindungsproteine
DE68927456D1 (de) RNS-Katalysator zur Spaltung von spezifischen RNS-Sequenzen
DE60213803D1 (en) Happier mapping
DE60226182D1 (de) Agarase und Gen dafür
DE69831007D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
EE200100040A (et) Meetod raku fenotüüpi muutva modulaatori identifitseerimiseks ja valmistamiseks, sihtmärkbiomolekulide eraldamiseks ja/või samastamiseks ning meditsiinitoote arendamiseks ja valmistamiseks
DE50210818D1 (de) Verfahren zur genexpression
EP1369477A4 (de) KONSTRUKTIONSVERFAHREN FÜR EIN cDNA-TAG ZUR IDENTIFIZIERUNG EINES EXPRIMIERTEN GENS UND VERFAHREN ZUR ANALYSE DER GENEXPRESSION
SE9403805D0 (sv) Method of preparing oligonucleotide probes or primers, vector therefor and use thereof
DE59901930D1 (de) Expressionssystem zur produktion von proteinen
WO2003043580A3 (en) Methods for identifying and validating potential drug targets
DK1180138T3 (da) Polynukleotidmotor, motorsystem, fremstilling og anvendelse deraf
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
PT983366E (pt) Adn que codifica uma sintetase de quitina de artropode
YU4101A (sh) Novi postupci za identifikovanje liganada i ciljnih biomolekula

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1696038

Country of ref document: EP